Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post–2021 Guidelines: Are Economic Barriers Finally Coming Down?. (31st December 2021)

• Record Type: Journal Article
• Authors: Fang, Noah; Ha, David; Dong, Kimberly; Leung, Thomas; Lee, Sydney; Holubar, Marisa; Meng, Lina
• Is Part Of: Clinical infectious diseases. Volume 75:Number 3(2022)
• Page Start: 519
• Page End: 521
• Publication Date: 2021-12-31
• Subjects: Clostridioides difficile -- formulary -- vancomycin -- fidaxomicin; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciab1061
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We reviewed Clostridioides difficile– positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0–$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.